Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

AstraZeneca (AZN) is highlighted by Zacks as a compelling long-term growth stock, despite its #3 (Hold) Zacks Rank, due to its strong 'A' VGM Score and 'B' Growth Style Score. The biopharmaceutical firm projects 11.4% year-over-year earnings growth for the current fiscal year, supported by six upward analyst revisions for fiscal 2025, which raised the Zacks Consensus Estimate to $4.58 per share. Coupled with an average earnings surprise of +3.5%, these factors indicate AZN's potential for continued outperformance and warrant investor consideration.

Analysis

AstraZeneca (AZN) presents a compelling growth profile despite its neutral Zacks #3 (Hold) rating. The company's forward-looking fundamentals appear robust, as indicated by a top-tier 'A' VGM Score and a strong 'B' Growth Style Score. This is substantiated by a projected year-over-year earnings growth of 11.4% for the current fiscal year. Analyst sentiment is notably positive for the medium term; for fiscal 2025, six analysts have revised their earnings estimates upward within the last 60 days, pushing the consensus estimate up by $0.09 to $4.58 per share. Furthermore, AZN has a track record of exceeding expectations, demonstrated by an average positive earnings surprise of 3.5%. The combination of these factors—strong projected growth, positive estimate revisions, and consistent earnings beats—suggests underlying strength that may not be fully reflected in its current 'Hold' recommendation.

Key Decisions for Investors

• Growth-oriented investors should look past the neutral Zacks #3 (Hold) rank and consider the stock's strong underlying growth metrics, including the 11.4% forecasted earnings growth and positive analyst revisions.
• Investors should monitor the trend in analyst earnings estimate revisions for fiscal 2025, as continued upward momentum could serve as a catalyst for a potential rating upgrade and price appreciation.
• Given the combination of a neutral rank with strong growth indicators, AZN may be suitable for a long-term hold strategy, but investors should weigh the possibility that near-term upside could be limited until the positive fundamental outlook translates into stronger price momentum.